Molecularly-Targeted Radiation

What is MTR?

Telix is developing a pipeline of molecularly-targeted radiation (MTR) therapies to image and treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumours and delivers a radioactive payload in a highly selective way; killing cancer cells, shrinking tumours and halting their growth. MTR therapies are very selective and are typically well tolerated by patients.
Telix Images-01
This approach contrasts with the traditional external beam radiation, where a linear accelerator externally targets and delivers beams of ionising radiation to tissues, often with significant collateral damage that can limit application.

Advantage of MTR

Most targeted therapies only kill a subset of cancer cells in the tumour microenvironment. MTR therapies are designed to destroy the tumour target plus adjacent tumour cells, regardless of their receptor or antigen profile.

In Summary
MTR products such as those offered by Telix Pharmaceuticals offer significant benefits :

  • Effective and well-tolerated
  • Designed to couple both imaging and therapy
  • Offer precise, modern imaging to map a patient’s cancer with a high degree of accuracy to inform treatment decisions
  • Can be used in combination with traditional cancer therapies
  • Can be easily integrated with standard care

General Resources

  • Charles Sturt University series on theranostics (diagnostic/therapy pairs) for potential patients, their families or carers.
    Part 1
    Part 2
    Part 3
  • Professor Richard Baum – Theranostics for prostate cancer
  • Unicorn Foundation– Australian not-for-profit medical charity focused on neuroendocrine tumours (NET)
  • Review article by Professor Richard Baum and Harshard Kulkarni on molecular imaging and personalised radionuclide therapies
  • Paper by Professor Rodney Hicks and colleagues on somatostatin receptor imaging with 68Gallium DOTATATE and PET/CT